Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;29:1031-1038

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bohlender, J.
Right arrow Articles by Ganten, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bohlender, J.
Right arrow Articles by Ganten, D.

(Hypertension. 1997;29:1031-1038.)
© 1997 American Heart Association, Inc.


Articles

Dose Effects of Human Renin in Rats Transgenic for Human Angiotensinogen

Jürgen Bohlender; Joel Ménard; Friedrich C. Luft; ; Detlev Ganten

From the Franz Volhard Clinic and Max Delbrück Center for Molecular Medicine, Humboldt University of Berlin (Germany), and Institut National de la Santé et de la Recherche Médicale (INSERM) U367, Paris, France (J.M.).

Correspondence to Jürgen Bohlender, MD, Franz Volhard Clinic, Humboldt University, Wiltbergstrasse 50, D-13122 Berlin-Buch, FRG.

Abstract We examined the effect of chronic human renin infusion and human renin inhibition on blood pressure in a unique transgenic rat model. We infused incremental doses of human renin (1 to 500 ng/h) with minipumps for 10 days into rats harboring the human angiotensinogen gene [TGR(hAOGEN)1623]. We measured blood pressure and heart rate continuously by telemetry. We found that human renin at 5 ng/h was necessary to increase blood pressure, whereas 10 ng/h caused systolic blood pressure to increase to 215±13 mm Hg. Heart rate decreased initially but then increased by 100 beats per minute compared with basal values. Drinking behavior also increased. Doses as high as 500 ng/h did not increase blood pressure further. A linear relationship was found between the log of plasma renin activity and systolic blood pressure that increased in slope from days 2 to 9. Rat angiotensinogen levels were low and not influenced by human renin infusion. Human angiotensinogen levels remained stable until 500 ng/h human renin was infused, at which time they decreased by 50% at 9 days. Rat renin gene expression (RNase protection assay) was decreased by human renin infusion, whereas rat and human angiotensinogen gene expressions in liver and kidney as well as angiotensin-converting enzyme gene expression in kidney were not affected. The human renin inhibitor Ro 42-5892 was given by gavage repeatedly to rats receiving human renin at 40 ng/h. Ro 42-5892 lowered blood pressure promptly to basal values. High human renin hypertension in this model is dose dependent, features a steeper relationship between blood pressure and plasma renin activity over time, and is associated with tachycardia and increased drinking. We conclude that the human angiotensinogen transgenic rat offers new perspectives in the study of human renin–induced hypertension.


Key Words: renin • angiotensinogen • rats, transgenic • gene expression




This article has been cited by other articles:


Home page
Circ. Res.Home page
I. Szokodi, P. Tavi, G. Foldes, S. Voutilainen-Myllyla, M. Ilves, H. Tokola, S. Pikkarainen, J. Piuhola, J. Rysa, M. Toth, et al.
Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility
Circ. Res., September 6, 2002; 91(5): 434 - 440.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. BOHLENDER, D. GANTEN, and F. C. LUFT
Rats Transgenic for Human Renin and Human Angiotensinogen as a Model for Gestational Hypertension
J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2056 - 2061.
[Abstract] [Full Text]


Home page
HypertensionHome page
J. Bohlender, J. Menard, D. Ganten, and F. C. Luft
Angiotensinogen Concentrations and Renin Clearance : Implications for Blood Pressure Regulation
Hypertension, March 1, 2000; 35(3): 780 - 786.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. H. Anderson, A. M. Devlin, D. Graham, J. J. Morton, C. A. Hamilton, J. L. Reid, N. J. Schork, and A. F. Dominiczak
Telemetry for Cardiovascular Monitoring in a Pharmacological Study : New Approaches to Data Analysis
Hypertension, January 1, 1999; 33(1): 248 - 255.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Bohlender, J. Menard, O. Edling, D. Ganten, and F. C. Luft
Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats
Am J Physiol Heart Circ Physiol, May 1, 1998; 274(5): H1450 - H1456.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. N. Muller, W. Fischli, J.-P. Clozel, K. F. Hilgers, J. Bohlender, J. Menard, A. Busjahn, D. Ganten, and F. C. Luft
Local Angiotensin II Generation in the Rat Heart : Role of Renin Uptake
Circ. Res., January 23, 1998; 82(1): 13 - 20.
[Abstract] [Full Text] [PDF]